Yue Hsin Lin
Founder at LIN BIOSCIENCE, INC.
Net worth: 99 M $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Hao Yuan Chuang | M | 40 |
Belite Bio (HK) Ltd.
| 7 years |
Hung Wei Chen | F | 43 |
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | 12 years |
Wan Shan Chen | F | 38 |
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | 10 years |
Cheng Chi Wang | M | - |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 8 years |
Wei Jen Liang | M | - | 6 years | |
Hui Chun Wang | M | 78 | 6 years | |
Gary Clark Biddle | M | 72 | 2 years | |
John Longo | M | 55 | 2 years | |
San Chien Tu | M | - | 6 years | |
Nathan L. Mata | M | 58 |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | 3 years |
Yi Ta Lue | M | 47 | 2 years | |
Jennifer Wu | F | - | - | |
Lung Yeh Cho | M | - | 11 years | |
Chan Yue Li | M | 52 | 8 years | |
Ta Meng Tseng | M | 66 | 11 years | |
Cheng Wei Chu | M | - | 6 years | |
Fang Ming Hsu | M | - | 8 years | |
Hsien Hua Huang | M | - | 6 years | |
Ching Chen Chiu | F | 55 | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Max Chan | M | 56 | 9 years | |
Kuo Tung Chen | M | - | - | |
Yang Tsung Tsai | M | - | - | |
Hsiu Mei Huang | F | - | - | |
Cheng Te Yu | M | - | - | |
Huai Jen Su | M | - | - | |
Chen Tung Wang | M | - | - | |
Chih Chung Chien | M | - | - | |
Howard Lee | M | 62 | - | |
Wei Li Lin | M | - | - | |
Ming Chiu Wu | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Taiwan | 24 | 80.00% |
United States | 10 | 33.33% |
Hong Kong | 1 | 3.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Yue Hsin Lin
- Personal Network